Be the most trusted biotech company


Henlius to Present Three Preclinical Studies at AACR 2025

2025-04-01

The American Association for Cancer Research 2025 Annual Meeting (AACR 2025) is set to take place from April 25 to April 30 in Chicago, the United States. Henlius will share three latest preclinical research results from its pipeline programs. The results to be presented include the novel anti-PD-L1/VEGF bispecific antibody HLX37, a novel KAT6A/B inhibitors with best-in-class potential, and a first-in-class ADC linker-payload featuring a highly differentiated killing mechanism. AACR is the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research.

 

Henlius has maintained a differentiated innovation strategy and is committed to drive innovation in antibody technology to accelerate the development of potential "First-in-Class" and "Best-in-Class" molecules into clinical stages. The company has built a pipeline of about 50 molecules, including monoclonal antibodies (mAbs), polyclonal antibodies (pAbs), antibody-drug conjugates (ADCs), and fusion proteins. Meanwhile, Henlius also leverages cutting-edge technologies such as AI to address unmet clinical needs and enhance the translation of innovative achievements.

 

Details of the abstract are as follows:


Title: A novel anti-PD-L1/VEGF bispecific antibody (HLX37) with immune checkpoint inhibition, anti-angiogenic, and antineoplastic activities

Session Title: Overcoming Checkpoint Inhibition and Tumor Suppression

Form: Abstract and poster

Abstract Number: 7303

Date and Time: April 30, 2025, 9:00 AM-12:00 PM CST

Location: Poster Section 39, Board #18


Title: Discovery of a novel antibody-drug conjugate linker-payload with a distinct killing mechanism via prolonged unfolded protein response activation

Session Title: Drug Design, Synthesis, and Disposition

Form: Abstract and poster

Abstract Number: 5730

Date and Time: April 29, 2025, 2:00 PM-5:00 PM CST

Location: Poster Section 25, Board #1


Title: Identification of novel KAT6A/B inhibitors with enhanced antitumor activity and reduced hematologic toxicity

Session Title: Lead Identification and Optimization

Form: Abstract and poster

Abstract Number: 6976

Date and Time: April 30, 2025, 9:00 AM-12:00 PM CST

Location: Poster Section 25, Board #5